Top

International Journal of Colorectal Disease

Published in:

01-12-2012 | Original Article

Genetic variation in insulin pathway genes and distal colorectal adenoma risk

Authors: A. Joan Levine, Ugonna Ihenacho, Won Lee, Jane C. Figueiredo, David J. Vandenberg, Christopher K. Edlund, Brian D. Davis, Mariana C. Stern, Robert W. Haile

Published in: International Journal of Colorectal Disease | Issue 12/2012

Abstract

Background

Insulin, glucose, and other insulin-related proteins that mediate insulin signaling are associated with colorectal neoplasia risk, but associations with common genetic variation in insulin axis genes are less clear. In this study, we used a comprehensive tag single-nucleotide polymorphisms (SNPs) approach to define genetic variation in six insulin axis genes (IGF1, IGF2, IGFBP1, IGFBP3, IRS1, and IRS2) and three genes associated with estrogen signaling (ESR1, ESR2, and PGR).

Methods

We assessed associations between SNPs and distal colorectal adenoma (CRA) risk in a case–control study of 1,351 subjects. Cases were individuals with one or more adenomas diagnosed during sigmoidoscopy, and controls were individuals with no adenomas at the sigmoidoscopy exam. We used unconditional logistic regression assuming an additive model to assess SNP-specific risks adjusting for multiple comparisons with P _act.

Results

Distal adenoma risk was significantly increased for one SNP in IGF2 [per minor allele OR = 1.41; 95 % confidence interval (CI) = 1.16, 1.67; P _act = 0.005] and decreased for an ESR2 SNP (per minor allele OR = 0.78; 95 % CI = 0.66, 0.91; P _act = 0.041). There was no statistically significant heterogeneity of these associations by race, sex, BMI, physical activity, or, in women, hormone replacement therapy use. Risk estimates did not differ in the colon versus rectum or for smaller (<1 cm) versus larger (>1 cm) adenomas.

Conclusions

These data suggest that selected genetic variability in IGF2 and ESR2 may be modifiers of CRA risk.

Available only for authorised users

Komninou D, Ayonote A, Richie JP Jr, Rigas B (2003) Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood) 228(4):396–405

Giovannucci E (1995) Insulin and colon cancer. Cancer Causes Control 6(2):164–179PubMedCrossRef

McKeown-Eyssen G (1994) Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3(8):687–695PubMed

Gunter MJ, Hayes RB, Chatterjee N, Yeager M, Welch R, Schoen RE, Yakochi L, Schatzkin A, Peters U (2007) Insulin resistance-related genes and advanced left-sided colorectal adenoma. Cancer Epidemiol Biomarkers Prev 16(4):703–708PubMedCrossRef

LeRoy EC, Moore JH, Hu C, Martinez ME, Lance P, Duggan D, Thompson PA (2011) Genes in the insulin and insulin-like growth factor pathway and odds of metachronous colorectal neoplasia. Hum Genet 129(5):503–512PubMedCrossRef

Pechlivanis S, Pardini B, Bermejo JL, Wagner K, Naccarati A, Vodickova L, Novotny J, Hemminki K, Vodicka P, Forsti A (2007) Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect. Endocr Relat Cancer 14(3):733–740PubMedCrossRef

Slattery ML, Samowitz W, Curtin K, Ma KN, Hoffman M, Caan B, Neuhausen S (2004) Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 13(7):1206–1214PubMed

Wernli KJ, Newcomb PA, Wang Y, Makar KW, Shadman M, Chia VM, Burnett-Hartman A, Wurscher MA, Zheng Y, Mandelson MT (2010) Body size, IGF and growth hormone polymorphisms, and colorectal adenomas and hyperplastic polyps. Growth Horm IGF Res 20(4):305–309PubMedCrossRef

Chen MJ, Longnecker MP, Morgenstern H, Lee ER, Frankl HD, Haile RW (1998) Recent use of hormone replacement therapy and the prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 7(3):227–230PubMed

10.

Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Fuchs C, Stampfer MJ (1998) Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 128(9):705–712PubMed

11.

Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288(7):872–881PubMedCrossRef

12.

Potter JD, Bostick RM, Grandits GA, Fosdick L, Elmer P, Wood J, Grambsch P, Louis TA (1996) Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case–Control Study. Cancer Epidemiol Biomarkers Prev 5(10):779–784PubMed

13.

Purdue MP, Mink PJ, Hartge P, Huang WY, Buys S, Hayes RB (2005) Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States). Cancer Causes Control 16(8):965–973PubMedCrossRef

14.

Terry MB, Neugut AI, Bostick RM, Sandler RS, Haile RW, Jacobson JS, Fenoglio-Preiser CM, Potter JD (2002) Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 11(7):622–629PubMed

15.

Barros RP, Machado UF, Gustafsson JA (2006) Estrogen receptors: new players in diabetes mellitus. Trends Mol Med 12(9):425–431PubMedCrossRef

16.

Brown LM, Gent L, Davis K, Clegg DJ (2010) Metabolic impact of sex hormones on obesity. Brain Res 1350:77–85PubMedCrossRef

17.

Kennelly R, Kavanagh DO, Hogan AM, Winter DC (2008) Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 9(4):385–391PubMedCrossRef

18.

Rondini EA, Harvey AE, Steibel JP, Hursting SD, Fenton JI (2011) Energy balance modulates colon tumor growth: interactive roles of insulin and estrogen. Mol Carcinog 50(5):370–382PubMedCrossRef

19.

Yakar S, Nunez NP, Pennisi P, Brodt P, Sun H, Fallavollita L, Zhao H, Scavo L, Novosyadlyy R, Kurshan N, Stannard B, East-Palmer J, Smith NC, Perkins SN, Fuchs-Young R, Barrett JC, Hursting SD, LeRoith D (2006) Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology 147(12):5826–5834PubMedCrossRef

20.

Leung KC, Xu A, Craig ME, Martin A, Lam KS, O'Sullivan AJ (2009) Adiponectin isoform distribution in women—relationship to female sex steroids and insulin sensitivity. Metabolism 58(2):239–245PubMedCrossRef

21.

Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE (2006) Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8(5):538–554PubMedCrossRef

22.

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Howard BV, Wylie-Rosett J, Anderson GL, Ho GY, Kaplan RC, Li J, Xue X, Harris TG, Burk RD, Strickler HD (2008) Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 68(1):329–337PubMedCrossRef

23.

Lin J, Zee RY, Liu KY, Zhang SM, Lee IM, Manson JE, Giovannucci E, Buring JE, Cook NR (2010) Genetic variation in sex-steroid receptors and synthesizing enzymes and colorectal cancer risk in women. Cancer Causes Control 21(6):897–908PubMedCrossRef

24.

Rudolph A, Sainz J, Hein R, Hoffmeister M, Frank B, Forsti A, Brenner H, Hemminki K, Chang-Claude J (2011) Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. Endocr Relat Cancer 18(3):371–384PubMedCrossRef

25.

Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, von Schonfels W, Hampe J, Schafmayer C, Volzke H, Frank B, Brenner H, Forsti A, Hemminki K, Chang-Claude J (2011) Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer 18(2):265–276PubMedCrossRef

26.

Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, Caan BJ, Samowitz W (2005) Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 14(12):2936–2942PubMedCrossRef

27.

Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW (2006) XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 15(12):2384–2390PubMedCrossRef

28.

Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC (1992) Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol 135(10):1114–1126, discussion 1127–1136PubMed

29.

Stram DO, Hankin JH, Wilkens LR, Pike MC, Monroe KR, Park S, Henderson BE, Nomura AM, Earle ME, Nagamine FS, Kolonel LN (2000) Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles. Am J Epidemiol 151(4):358–370PubMedCrossRef

30.

Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265PubMedCrossRef

31.

Shen R, Fan JB, Campbell D, Chang W, Chen J, Doucet D, Yeakley J, Bibikova M, Wickham Garcia E, McBride C, Steemers F, Garcia F, Kermani BG, Gunderson K, Oliphant A (2005) High-throughput SNP genotyping on universal bead arrays. Mutat Res 573(1–2):70–82PubMed

32.

Consortium TIH (2005) A haplotype map of the human genome. Nature 437(7063):1299–1320CrossRef

33.

Levine AJ, Siegmund KD, Ervin CM, Diep A, Lee ER, Frankl HD, Haile RW (2000) The methylenetetrahydrofolate reductase 677C–>T polymorphism and distal colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 9(7):657–663PubMed

34.

Conneely KN, Boehnke M (2007) So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet 81(6):1158–1168PubMedCrossRef

35.

Chen X, Guan J, Song Y, Chen P, Zheng H, Tang C, Wu Q (2008) IGF-I (CA) repeat polymorphisms and risk of cancer: a meta-analysis. J Hum Genet 53(3):227–238PubMedCrossRef

36.

Morris JK, George LM, Wu T, Wald NJ (2006) Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer 95(1):112–117PubMedCrossRef

37.

Pisani P (2008) Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 114(1):63–70PubMedCrossRef

38.

Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353PubMedCrossRef

39.

Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C, Palli D, Tumino R, Vineis P, Peeters PH, van Gils CH, Bueno-de-Mesquita BH, Vrieling A, Allen NE, Roddam A, Bingham S, Khaw KT, Manjer J, Borgquist S, Dumeaux V, Torhild Gram I, Lund E, Trichopoulou A, Makrygiannis G, Benetou V, Molina E, Donate Suarez I, Barricarte Gurrea A, Gonzalez CA, Tormo MJ, Altzibar JM, Olsen A, Tjonneland A, Gronbaek H, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Slimani N, Boffetta P, Jenab M, Riboli E, Kaaks R (2010) Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 126(7):1702–1715PubMed

40.

Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X, Shen H (2009) Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 17(12):1668–1675PubMedCrossRef

41.

Li L, Huang X, Huo K (2010) IGFBP3 polymorphisms and risk of cancer: a meta-analysis. Mol Biol Rep 37(1):127–140PubMedCrossRef

42.

Pechlivanis S, Wagner K, Chang-Claude J, Hoffmeister M, Brenner H, Forsti A (2007) Polymorphisms in the insulin like growth factor 1 and IGF binding protein 3 genes and risk of colorectal cancer. Cancer Detect Prev 31(5):408–416PubMedCrossRef

43.

Furstenberger G, Senn HJ (2002) Insulin-like growth factors and cancer. Lancet Oncol 3(5):298–302PubMedCrossRef

44.

Hassan AB, Howell JA (2000) Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc ^Min/+ mice. Cancer Res 60(4):1070–1076PubMed

45.

Kaneda A, Feinberg AP (2005) Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 65(24):11236–11240PubMedCrossRef

46.

Kaneda A, Wang CJ, Cheong R, Timp W, Onyango P, Wen B, Iacobuzio-Donahue CA, Ohlsson R, Andraos R, Pearson MA, Sharov AA, Longo DL, Ko MS, Levchenko A, Feinberg AP (2007) Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci U S A 104(52):20926–20931PubMedCrossRef

47.

Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom WS, Okano H, Ko MS, Ohlsson R, Longo DL, Feinberg AP (2005) Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307(5717):1976–1978PubMedCrossRef

48.

Woodson K, Flood A, Green L, Tangrea JA, Hanson J, Cash B, Schatzkin A, Schoenfeld P (2004) Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J Natl Cancer Inst 96(5):407–410PubMedCrossRef

49.

Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP (1998) Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 4(11):1276–1280PubMedCrossRef

50.

Ito Y, Koessler T, Ibrahim AE, Rai S, Vowler SL, Abu-Amero S, Silva AL, Maia AT, Huddleston JE, Uribe-Lewis S, Woodfine K, Jagodic M, Nativio R, Dunning A, Moore G, Klenova E, Bingham S, Pharoah PD, Brenton JD, Beck S, Sandhu MS, Murrell A (2008) Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet 17(17):2633–2643PubMedCrossRef

51.

Kinouchi Y, Hiwatashi N, Higashioka S, Nagashima F, Chida M, Toyota T (1996) Relaxation of imprinting of the insulin-like growth factor II gene in colorectal cancer. Cancer Lett 107(1):105–108PubMedCrossRef

52.

Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, de La Chapelle A (2001) Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci U S A 98(2):591–596PubMedCrossRef

53.

Nishihara S, Hayashida T, Mitsuya K, Schulz TC, Ikeguchi M, Kaibara N, Oshimura M (2000) Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability. Int J Oncol 17(2):317–322PubMed

54.

Sasaki J, Konishi F, Kawamura YJ, Kai T, Takata O, Tsukamoto T (2006) Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2. Int J Cancer 119(1):80–83PubMedCrossRef

55.

Tanaka K, Shiota G, Meguro M, Mitsuya K, Oshimura M, Kawasaki H (2001) Loss of imprinting of long QT intronic transcript 1 in colorectal cancer. Oncology 60(3):268–273PubMedCrossRef

56.

Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR, Feinberg AP (2003) Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299(5613):1753–1755PubMedCrossRef

57.

Liou JM, Wu MS, Lin JT, Wang HP, Huang SP, Chiu HM, Lee YC, Lin YB, Shun CT, Liang JT (2007) Loss of imprinting of insulin-like growth factor II is associated with increased risk of proximal colon cancer. Eur J Cancer 43(8):1276–1282PubMedCrossRef

58.

Kaaks R, Stattin P, Villar S, Poetsch AR, Dossus L, Nieters A, Riboli E, Palmqvist R, Hallmans G, Plass C, Friesen MD (2009) Insulin-like growth factor-II methylation status in lymphocyte DNA and colon cancer risk in the Northern Sweden Health and Disease cohort. Cancer Res 69(13):5400–5405PubMedCrossRef

59.

Foryst-Ludwig A, Kintscher U (2010) Metabolic impact of estrogen signalling through ERalpha and ERbeta. J Steroid Biochem Mol Biol 122(1–3):74–81PubMedCrossRef

60.

Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 47(7):1175–1187PubMedCrossRef

61.

Ribas V, Nguyen MT, Henstridge DC, Nguyen AK, Beaven SW, Watt MJ, Hevener AL (2010) Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. Am J Physiol Endocrinol Metab 298(2):E304–E319PubMedCrossRef

62.

Barone M, Tanzi S, Lofano K, Scavo MP, Pricci M, Demarinis L, Papagni S, Guido R, Maiorano E, Ingravallo G, Comelli MC, Francavilla A, Di Leo A (2010) Dietary-induced ERbeta upregulation counteracts intestinal neoplasia development in intact male Apc^Min/+ mice. Carcinogenesis 31(2):269–274PubMedCrossRef

63.

Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Strom A, Gustafsson JA (2009) Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 69(15):6100–6106PubMedCrossRef

64.

Martineti V, Picariello L, Tognarini I, Carbonell Sala S, Gozzini A, Azzari C, Mavilia C, Tanini A, Falchetti A, Fiorelli G, Tonelli F, Brandi ML (2005) ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Relat Cancer 12(2):455–469PubMedCrossRef

65.

Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, Omoto Y, Warner M, Gustafsson JA (2006) Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci U S A 103(8):2959–2964PubMedCrossRef

66.

Weige CC, Allred KF, Allred CD (2009) Estradiol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon. Cancer Res 69(23):9118–9124PubMedCrossRef

67.

Honma N, Arai T, Takubo K, Younes M, Tanaka N, Mieno MN, Tamura K, Ikeda S, Sawabe M, Muramatsu M (2011) Oestrogen receptor-beta CA repeat polymorphism is associated with incidence of colorectal cancer among females. Histopathology 59(2):216–224PubMed

Title: Genetic variation in insulin pathway genes and distal colorectal adenoma risk
Authors: A. Joan Levine
Ugonna Ihenacho
Won Lee
Jane C. Figueiredo
David J. Vandenberg
Christopher K. Edlund
Brian D. Davis
Mariana C. Stern
Robert W. Haile
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 12/2012
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-012-1505-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genetic variation in insulin pathway genes and distal colorectal adenoma risk

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2012

A clinicopathological study of serotonin of sigmoid colon mucosa in association with chronic symptoms in uncomplicated diverticulosis

Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature

Prevention of major infectious complications by pre-emptive enterostomy in patients awaiting allogeneic stem cell transplantation

Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: results from a prospective, randomised, single-centre, pilot clinical trial

Five-year risk of colorectal neoplasia after normal baseline colonoscopy in asymptomatic Chinese Mongolian over 50 years of age

Influence of size and complexity of the hospitals in an enhanced recovery programme for colorectal resection